12:00 AM
 | 
Oct 12, 2015
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aristada aripiprazole lauroxil regulatory update

FDA approved Aristada aripiprazole lauroxil from Alkermes to treat schizophrenia. The company plans to launch the injectable, extended-release formulation of aripiprazole using LinkeRx technology “immediately.” Alkermes said...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >